Friday, January 9, 2015

DiaCarta Gets $8M For Molecular Diagnostics

Hayward, California- and Shanghai-based DiaCarta, a startup developing molecular diagnostics products, said today that it has raised $8M in a Series A funding round. The funding came from BVCF (BioVeda China Fund). As part of the funding, Weixin Xu of BVCF joins the company's board. DiaCarta is developing molecular diagnostics products aimed at detecting mutations in cervical, oral cancer, and in other areas. More information »